Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Plans Need Six Months To Review New Drugs, Blues Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft formulary guidelines’ requirement that plans make a coverage decision for new chemical entities within 90 days is too short, Horizon Blue Cross Blue Shield exec tells CMS. Independence Blue Cross exec says longer review period will help ensure drug safety in light of faster FDA review times.

You may also be interested in...



Medicare P&Ts Would Follow Pharmacist Groups’ Principles Under CMS Draft

Pharmacy & therapeutics committee principles developed by the American Society of Health System Pharmacists and Academy of Managed Care Pharmacy will serve as guidelines for Part D drug plans, CMS draft formulary guidelines say. The guidelines also list standards CMS will use in approving formularies.

Medicare Rx Coverage Rules Could Compromise Beneficiary Safety – Blues Exec

Some drug classes with a two-drug coverage requirement could force plans to cover a product they consider to be less safe than another in the class, Excellus BlueCross BlueShield exec says. An internal analysis finds drug costs will rise at least 3.5% if U.S. Pharmacopeia’s “recommended subdivisions” are turned into classes.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Topics

UsernamePublicRestriction

Register

PS058378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel